DK2575768T3 - Vandig dispergering omfattende galactolipider og fremgangsmåde til fremstilling deraf - Google Patents
Vandig dispergering omfattende galactolipider og fremgangsmåde til fremstilling deraf Download PDFInfo
- Publication number
- DK2575768T3 DK2575768T3 DK11786992.5T DK11786992T DK2575768T3 DK 2575768 T3 DK2575768 T3 DK 2575768T3 DK 11786992 T DK11786992 T DK 11786992T DK 2575768 T3 DK2575768 T3 DK 2575768T3
- Authority
- DK
- Denmark
- Prior art keywords
- ethanol
- oil
- water
- polar lipids
- lipids
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 147
- 239000006185 dispersion Substances 0.000 title claims description 127
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 443
- 150000002632 lipids Chemical class 0.000 claims description 290
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 139
- 239000000203 mixture Substances 0.000 claims description 121
- 239000002245 particle Substances 0.000 claims description 116
- 230000008569 process Effects 0.000 claims description 83
- 239000002904 solvent Substances 0.000 claims description 68
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 65
- 238000010790 dilution Methods 0.000 claims description 56
- 239000012895 dilution Substances 0.000 claims description 56
- 239000002502 liposome Substances 0.000 claims description 56
- 235000007319 Avena orientalis Nutrition 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 45
- 235000013305 food Nutrition 0.000 claims description 23
- 238000001246 colloidal dispersion Methods 0.000 claims description 17
- 150000003904 phospholipids Chemical class 0.000 claims description 17
- 238000001704 evaporation Methods 0.000 claims description 14
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000008961 swelling Effects 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 230000002269 spontaneous effect Effects 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 4
- 150000002888 oleic acid derivatives Chemical class 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 238000000386 microscopy Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 2
- 241000209761 Avena Species 0.000 claims 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 238000004945 emulsification Methods 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- 239000012071 phase Substances 0.000 description 184
- 239000003921 oil Substances 0.000 description 110
- 235000019198 oils Nutrition 0.000 description 108
- 244000075850 Avena orientalis Species 0.000 description 48
- 230000015572 biosynthetic process Effects 0.000 description 35
- 239000000047 product Substances 0.000 description 29
- 208000008589 Obesity Diseases 0.000 description 27
- 235000020824 obesity Nutrition 0.000 description 27
- 239000007787 solid Substances 0.000 description 25
- 238000009826 distribution Methods 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 239000000306 component Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 230000036186 satiety Effects 0.000 description 16
- 235000019627 satiety Nutrition 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 239000002691 unilamellar liposome Substances 0.000 description 13
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 238000010587 phase diagram Methods 0.000 description 11
- 230000001804 emulsifying effect Effects 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 9
- 239000012467 final product Substances 0.000 description 9
- 241000209140 Triticum Species 0.000 description 8
- 235000021307 Triticum Nutrition 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 229940074096 monoolein Drugs 0.000 description 8
- 238000010923 batch production Methods 0.000 description 7
- 235000013339 cereals Nutrition 0.000 description 7
- 150000002149 estolides Chemical class 0.000 description 7
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 7
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000003113 dilution method Methods 0.000 description 5
- 238000012377 drug delivery Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 5
- 230000007704 transition Effects 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229960001243 orlistat Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000001586 synchrotron small angle X-ray scattering Methods 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 206010053317 Hydrophobia Diseases 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 229940086609 Lipase inhibitor Drugs 0.000 description 3
- 239000000232 Lipid Bilayer Substances 0.000 description 3
- 244000027321 Lychnis chalcedonica Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005428 food component Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 206010041969 Steatorrhoea Diseases 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000004464 cereal grain Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical group C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000007863 gel particle Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 229960004232 linoleic acid Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000001162 steatorrhea Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- SIKWOTFNWURSAY-UHFFFAOYSA-N Lipstatin Natural products CCCCCCC1C(CC(CC=CCC=CCCCCC)C(=O)OC(CC(C)C)NC=O)OC1=O SIKWOTFNWURSAY-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- ZXSWTMLNIIZPET-ZOFHRBRSSA-N Normethandrolone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 ZXSWTMLNIIZPET-ZOFHRBRSSA-N 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 239000004990 Smectic liquid crystal Substances 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000003608 autoimmunological effect Effects 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 description 1
- 229950002397 cetilistat Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000019869 fractionated palm oil Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- OQMAKWGYQLJJIA-CUOOPAIESA-N lipstatin Chemical compound CCCCCC[C@H]1[C@H](C[C@H](C\C=C/C\C=C/CCCCC)OC(=O)[C@H](CC(C)C)NC=O)OC1=O OQMAKWGYQLJJIA-CUOOPAIESA-N 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002535 lyotropic effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 235000010958 polyglycerol polyricinoleate Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- -1 vesicles Substances 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0056—Spread compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0295—Liquid crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Claims (24)
1. Fremgangsmàde til fremstilling af en dispergering af polære lipider i en ethanol-vand-blanding, hvilke polære lipider omfatter galactolipider, kende-tegnet ved fortynding af en olie indeholdende polære lipider omfattende polar lipider omfattende galadolipider under anvendelse af en forste ethanol-vand-blanding med en ethanolkoncentration, beregnet som volumenprocent baseret pà den samlede mængde af ethanol og vand, som ligger i omràdet fra 15 volumenprocent-enheder under den kritiske polaritet af ethanol-vand-blandingen i forhold til oliën, til 15 volumenprocent-enheder over den kritiske polaritet, hvor den kritiske polaritet af den forste ethanol-vand-blanding ligger i omràdet 25-75 volumenprocent ethanol i vand-ethanol-blandingen, og hvor de polære lipider efter fortynding danner en lamelformet væske-krystallinsk fase, uden forst at danne en heksagonal Hll-fase, hvor den kritiske polaritet definerer oplosningsmiddelsystemets koncentration af ethanol og vand, nàr en oplosningsmiddel-i-olie-emulsion omdannes til en olie-i-oplosningsmiddel-emulsion, og den kritiske polaritet detekteres gennem viskositet eller mikro-skopi.
2. Fremgangsmàde ifolge krav 1, kendetegnet ved, at den forste ethanol-vand-blanding har en ethanolkoncentration beregnet som volumenprocent baseret pà den samlede mængde af ethanol og vand, som ligger i omràdet fra 10 volumenprocent-enheder, og fortrinsvis fra 5 volumenprocent-enheder, under den kritiske polaritet af ethanol-vand-blandingen i forhold til oliën, til 10 volumenprocent-enheder, og fortrinsvis til 5 volumenprocent-enheder, over den kritiske polaritet.
3. Fremgangsmàde ifolge krav 1 eller 2, kendetegnet ved at den kritiske polaritet af den forste ethanol-vand-blanding er i omràdet 30-70, fortrinsvis 35-65, mere foretrukket 40-60 og mest foretrukket i omràdet 45-55 volumenprocent ethanol i vand-ethanol-blandingen.
4. Fremgangsmàde ifolge et hvilket som helst af kravene 1-3, kendetegnet ved at fortynding af dispergeringen fortsættes med den forste ethanol-vand-blanding og/eller en anden ethanol-vand-blanding og/eller med vand, indtil der opnàs en kolloidal dispergering af de polære lipider, hvor de polære lipi- der danner kolloidale partikler i form af liposomer, kubiske partikler og/eller oliesmàdràber, der er coatede med en lamelformet væske-krystallinsk fase.
5. Fremgangsmäde ifolge krav 4, kendetegnet ved, at forholdet i volumenprocent mellem ethanol og vand i den anden ethanol-vand-blanding, der an-vendes til fortynding af de polære lipider, som danner en lamelformet væske-krystallinsk fase i den forste ethanol-vand-blanding, er anderledes end i den forste ethanol-vand-blanding, säledes at den anden ethanol-vand-blanding indeholder en hojere andel af vand end den forste polære oplosningsmiddel-blanding.
6. Fremgangsmäde ifolge et hvilket som helst af de foregäende krav, kendetegnet ved, at der efter den fortsatte fortynding af dispergeringen omfattende de polære lipider i en lamelformet væske-krystallinsk fase opnàs en kolloidal dispergering af liposomer.
7. Fremgangsmäde ifolge et hvilket som helst af kravene 1-5, kendetegnet ved, at olien indeholder mindst 25 vægtprocent monoglycerider af olie-og/eller linolsyre beregnet i forhold til den samlede mængde af lipider i olien, hvor der efter den fortsatte fortynding af dispergeringen omfattende de polære lipider dannes en kolloidal dispergering af kubosomer.
8. Fremgangsmäde ifolge et hvilket som helst af de foregäende krav, kendetegnet ved evaporering af ethanol fra dispergeringen til tilvejebringelse af en vandig dispergering indeholdende mindre end 10 vægtprocent, fortrinsvis mindre end 5 vægtprocent og mere foretrukket mindre end 1 vægtprocent ethanol.
9. Fremgangsmäde ifolge et hvilket som helst af de foregäende krav, kendetegnet ved, at de polære lipider ogsä omfatter phospholipider.
10. Fremgangsmäde ifolge et hvilket som helst af kravene 1-5, kendetegnet ved, at olien indeholder mellem 30-95, fortrinsvis mellem 30-90 lipidprocent ikke-polære lipider, og at dispergeringen indeholder mindst 30 vægtprocent, fortrinsvis mindst 40 vægtprocent og mere foretrukket mindst 50 vægtprocent samlede lipider, hvilket forer til en olie-i-vand-emulsion, hvori de ikke-polære lipider danner oliesmàdràber, der er coatede med en lamelformet væske-krystallinsk fase af de polære lipider.
11. Fremgangsmäde ifolge et hvilket som helst af kravene 1-3, kendetegnet ved evaporering af ethanol og vand fra dispergeringen til tilvejebringelse af en olie, som indeholder mindre end 1 vægtprocent ethanol.
12. Vandig kolloidal dispergering af polære lipider, hvilke polære lipider om-fatter galactolipider, kendetegnet ved, at den vandige kolloidale disperge-ring kan opnàs ved fremgangsmàden ifolge krav 1 efterfulgt af fortsat fortyn-ding af dispergeringen omfattende polære lipider i en lamelformet væske-krystallinsk fase, hvor de polære lipider, der omfatter galactolipider, danner liposomer omfattende mindst 50 lipidprocent polære lipider og mindst 2 lipid-procent ikke-polære lipider, hvor lipidprocent refererer til vægtprocenten af henholdsvis polære lipider og ikke-polære lipider, beregnet i forhold til den samlede mængde af lipider.
13. Dispergering ifolge krav 12, kendetegnet ved, at liposomerne er af na-nostorrelse med en gennemsnitsdiameter, som er mindre end 100 nm, og mindst 80 % af liposomerne har en diameter pà mindre end 200 nm.
14. Vandig kolloidal dispergering af polære lipider og ikke-polære lipider, hvor mindst 25 vægtprocent er monoglycerider af olie- og/eller linolsyre beregnet i forhold til den samlede mængde af lipider, hvilke polære lipider omfatter galactolipider, kendetegnet ved, at de polære lipider omfattende galactolipider og monoglyceriderne danner kolloidale kubosomer.
15. Dispergering ifolge et hvilket som helst af kravene 12-14, kendetegnet ved, at de polære lipider ogsà omfatter phospholipider.
16. Dispergering ifolge et hvilket som helst af kravene 12-15, kendetegnet ved, at liposomerne og/eller kubosomerne indeholder mindst 60 lipidprocent, fortrinsvis mindst 75 lipidprocent polære lipider, idet resten af lipiderne er ikke-polære lipider, hvor lipidprocent refererer til vægtprocenten af polære lipider beregnet i forhold til den samlede mængde af lipider.
17. Dispergering ifolge krav 16, kendetegnet ved at liposomerne indeholder mindst 5 lipidprocent, fortrinsvis mindst 10 lipidprocent af ikke-polære lipider, idet resten af lipiderne er polære lipider, hvor lipidprocenten refererer til vægtprocenten af ikke-polære lipider beregnet i forhold til den samlede mængde af lipider.
18. Vandig dispergering i form af en olie-i-vand-emulsion af polære lipider, der omfatter galactolipider, og ikke-polære lipider, kendetegnet ved, at de ikke-polære lipider danner oliesmàdràber, der er coatede med en lamelfor-met væske-krystallinsk fase af de polære lipider, hvor de polære lipider, der omfatter galactolipider, er af en type, der vil danne en heksagonal Hll-fase ved direkte eksponering for vand.
19. Olie indeholdende polære lipider, der omfatter galactolipider, kendetegnet ved, at olien kan opnäs ved fremgangsmäden ifolge krav 1 efterfulgt af evaporering af ethanol og vand fra dispergeringen til tilvejebringelse af en olie, der indeholder mindre end 1 vægtprocent ethanol og mindre end 3 vægtprocent sukker, fortrinsvis mindre end 2 vægtprocent sukker og mere end 25 vægtprocent polære lipider, fortrinsvis mere end 30 vægtprocent polære lipider, og olien er ogsà kendetegnet ved at danne mindre heksagonal fase end lamelformet væske-krystallinsk fase under en efterfolgende vand-opsvulmningsproces, som resulterer i en spontan emulgering.
20. Olie ifolge krav 19, kendetegnet ved, at olien stammer fra havre.
21. Vandig kolloidal dispergering og/eller olie, der kan opnàs i henhold til fremgangsmäden ifolge et hvilket som helst af kravene 1-11, eller ifolge et hvilket som helst af kravene 12-20, til anvendelse ved behandling af adiposi-tas.
22. Vandig kolloidal dispergering og/eller olie til anvendelse ifolge krav 21, hvor dispergeringen og/eller olien stammer fra havre.
23. Farmaceutisk formulering omfattende en vandig kolloidal dispergering og/eller olie, der kan opnàs i henhold til fremgangsmäden ifolge et hvilket som helst af kravene 1-11, eller ifolge et hvilket som helst af kravene 12-20, eventuelt med iblanding af en farmaceutisk acceptabel adjuvans, fortyn-dingsmiddel eller bærer, hvor dispergeringen og/eller oliën fungerer som en aktiv bestanddel eller som en bærer til frigivelse af en aktiv bestanddel.
24. Artikel omfattende en vandig kolloidal dispergering og/eller olie, der kan opnàs i henhold til fremgangsmàden ifolge et hvilket som helst af kravene 1-11, eller ifolge et hvilket som helst af kravene 12-20, hvor artiklen er udvalgt fra folgende gruppe af sammensætninger: en kosmetisk sammensætning, en fodevaresammensætning, et kosttilskud og/eller en dyrefodersammensæt-ning.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34764310P | 2010-05-24 | 2010-05-24 | |
| SE1050515 | 2010-05-24 | ||
| PCT/SE2011/050646 WO2011149416A1 (en) | 2010-05-24 | 2011-05-24 | Aqueous dispersion comprising galactolipids and method for production thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2575768T3 true DK2575768T3 (da) | 2018-03-12 |
Family
ID=45004194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11786992.5T DK2575768T3 (da) | 2010-05-24 | 2011-05-24 | Vandig dispergering omfattende galactolipider og fremgangsmåde til fremstilling deraf |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9237762B2 (da) |
| EP (1) | EP2575768B1 (da) |
| DK (1) | DK2575768T3 (da) |
| ES (1) | ES2662710T3 (da) |
| NO (1) | NO2575768T3 (da) |
| PL (1) | PL2575768T3 (da) |
| WO (1) | WO2011149416A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019005830A1 (en) * | 2017-06-26 | 2019-01-03 | Fordoz Pharma Corp. | NANOSOME FORMULATIONS OF APREPITANT AND METHODS AND APPLICATIONS THEREOF |
| WO2021077061A1 (en) * | 2019-10-18 | 2021-04-22 | Quicksilver Scientific, Inc. | Self-microemulsifying multi-deliverable systems |
| GB201916585D0 (en) * | 2019-11-14 | 2020-01-01 | Givaudan Sa | Concentrate |
| WO2025133121A2 (en) * | 2023-12-21 | 2025-06-26 | Emulsi Biotech Ab | Compositions and methods of making them |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| SE8505569D0 (sv) | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | Enteralt preparat |
| CA2182577C (en) * | 1994-02-04 | 2002-08-20 | Anders Carlsson | Lipophilic carrier preparations |
| WO1995020943A1 (en) * | 1994-02-04 | 1995-08-10 | Scotia Lipidteknik Ab | Oil-in-water emulsions |
| CN1083713C (zh) * | 1994-02-04 | 2002-05-01 | 利珀克尔集团公司 | 双层制剂 |
| JPH10508322A (ja) | 1995-10-12 | 1998-08-18 | スーパーゲン，インコーポレイティド | ５βステロイドのリポソーム配合物 |
| SE9702630D0 (sv) | 1997-07-07 | 1997-07-07 | Scotia Lipidteknik Ab | Satiety product |
| US6123959A (en) * | 1998-04-24 | 2000-09-26 | Univera Pharmaceuticals, Inc. | Aqueous composition comprising active ingredients for the de-pigmentation of the skin |
| AR022204A1 (es) | 1999-01-08 | 2002-09-04 | Norgine Bv | Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende. |
| US20020153508A1 (en) | 2000-06-29 | 2002-10-24 | Lynch Matthew Lawrence | Cubic liquid crystalline compositions and methods for their preparation |
| US6656385B2 (en) | 2001-02-21 | 2003-12-02 | The Procter & Gamble Company | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| US6936187B2 (en) | 2001-02-21 | 2005-08-30 | Matthew Lawrence Lynch | Functionalized cubic liquid crystalline phase materials and methods for their preparation and use |
| WO2003018529A1 (en) | 2001-08-24 | 2003-03-06 | Girouard Michael P | Monounsaturated fatty acids of at least 20 carbon atoms and perhydrocyclopentanophenanthrene nucleus combination molecules and their use as weight-loss agents |
| EP1817078A1 (en) | 2004-11-16 | 2007-08-15 | Unilever N.V. | Satiety emulsions and food compositions |
| MX2007013411A (es) | 2005-05-04 | 2008-01-15 | Unilever Nv | Emulsiones de saciedad y composiciones alimenticias. |
| CA2609208C (en) | 2005-06-10 | 2016-10-18 | Per-Ake Albertsson | Use of plant cell membrane for the treatment of obesity |
| PL1919450T3 (pl) * | 2005-09-01 | 2014-11-28 | Meda Ab | Kompozycja liposomowa zawierająca lek przeciwhistaminowy i kortykosteroid oraz jej zastosowanie do wytwarzania leku do leczenia nieżytu nosa i chorób spokrewnionych |
| WO2007075142A1 (en) | 2005-12-24 | 2007-07-05 | Dsm Ip Assets B.V. | Long term weight maintenance |
| EP3219307B1 (en) * | 2005-12-30 | 2021-09-08 | NuVessl Inc. | Nanolipidic particles |
| JP2007204368A (ja) | 2006-01-30 | 2007-08-16 | Sunstar Inc | 絹ペプチドを有効成分とするＮＦ−κＢ活性阻害剤及び経口組成物 |
| WO2009031436A1 (ja) | 2007-09-03 | 2009-03-12 | Dai Nippon Printing Co., Ltd. | 包装体とその製造方法及び装置 |
| WO2009068651A1 (en) * | 2007-11-28 | 2009-06-04 | Dsm Ip Assets B.V. | Lipid emulsion for human consumption |
| WO2009068661A1 (en) | 2007-11-29 | 2009-06-04 | Universiteit Maastricht | Device for thoracostomy |
| WO2009131436A1 (en) * | 2008-04-25 | 2009-10-29 | Campina Nederland Holding B.V. | Drinking yoghurt |
| CN101632637B (zh) * | 2008-07-22 | 2011-04-27 | 清华大学 | 一种多烯紫杉醇脂质制剂及其制备方法 |
-
2011
- 2011-05-24 NO NO11786992A patent/NO2575768T3/no unknown
- 2011-05-24 DK DK11786992.5T patent/DK2575768T3/da active
- 2011-05-24 EP EP11786992.5A patent/EP2575768B1/en active Active
- 2011-05-24 ES ES11786992.5T patent/ES2662710T3/es active Active
- 2011-05-24 US US13/699,663 patent/US9237762B2/en active Active
- 2011-05-24 WO PCT/SE2011/050646 patent/WO2011149416A1/en not_active Ceased
- 2011-05-24 PL PL11786992T patent/PL2575768T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2575768T3 (pl) | 2018-07-31 |
| WO2011149416A1 (en) | 2011-12-01 |
| NO2575768T3 (da) | 2018-05-12 |
| US20130129801A1 (en) | 2013-05-23 |
| EP2575768A1 (en) | 2013-04-10 |
| ES2662710T3 (es) | 2018-04-09 |
| US9237762B2 (en) | 2016-01-19 |
| EP2575768A4 (en) | 2014-07-02 |
| EP2575768B1 (en) | 2017-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ashaolu | Nanoemulsions for health, food, and cosmetics: a review | |
| Choi et al. | Nanoemulsions as delivery systems for lipophilic nutraceuticals: strategies for improving their formulation, stability, functionality and bioavailability: SJ Choi, DJ McClements | |
| McClements et al. | Enhancing nutraceutical performance using excipient foods: Designing food structures and compositions to increase bioavailability | |
| Zou et al. | Utilizing food matrix effects to enhance nutraceutical bioavailability: increase of curcumin bioaccessibility using excipient emulsions | |
| McClements et al. | Boosting the bioavailability of hydrophobic nutrients, vitamins, and nutraceuticals in natural products using excipient emulsions | |
| Tan et al. | Modulation of the carotenoid bioaccessibility through liposomal encapsulation | |
| Lv et al. | Vitamin E encapsulation in plant-based nanoemulsions fabricated using dual-channel microfluidization: Formation, stability, and bioaccessibility | |
| DK2548456T3 (da) | Emulsioner inklusive (indbefattende) et PEG-derivat af tocopherol | |
| AU2007212412B2 (en) | Dietary supplement composition for blood lipid health | |
| Roohinejad et al. | Emulsion-based systems for delivery of food active compounds: formation, application, health and safety | |
| Fatouros et al. | Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products | |
| MX2010010214A (es) | Derivados de vitamina e y sus usos. | |
| Sadeghpour et al. | Bile salts caught in the act: from emulsification to nanostructural reorganization of lipid self-assemblies | |
| JP2016128425A (ja) | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 | |
| JP2019205456A (ja) | 可食無機塩の粒子によって安定化されたエマルション | |
| CN107744024A (zh) | 亲水性的脂类组合物，其制备及调配方法和应用 | |
| Lin et al. | In vitro–in vivo study of the impact of excipient emulsions on the bioavailability and antioxidant activity of flavonoids: Influence of the carrier oil type | |
| DK2575768T3 (da) | Vandig dispergering omfattende galactolipider og fremgangsmåde til fremstilling deraf | |
| Mangrulkar et al. | A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin | |
| JP2004534793A (ja) | 安定化されたフィトステロールの油中分散液 | |
| EP3129003A1 (en) | Food matrices and methods of making and using | |
| Liang et al. | Improving the physicochemical stability of soy phospholipid-stabilized emulsions loaded with lutein by the addition of sphingomyelin and cholesterol: Inspired by a milk fat globule membrane | |
| Engström et al. | Microemulsions in foods | |
| US20240307474A1 (en) | Fermented Uni-sourced Nanoemulsion of Nigella sativa or Cannabis sativa For Use in Medical, Cosmetic, and Recreational Indications with a Method of Its Production and Use | |
| Kaur | Nanoemulsions as delivery vehicles for food and pharmaceuticals |